“In the fourth quarter of 2022, we traveled around the world sharing our message about the potential of oxMIF as an immuno-oncology and inflammation target. With our Series B raise underway and completion of several value-building projects I value this opportunity to update you on OncoOne’s progress and to close a very thrilling year 2022. As we continue to develop our oxMIF-targeting pipeline of monoclonal antibodies and prepare for our transition into the clinic, we would like to look back at the team’s accomplishments in Q4 as we prepare for an exciting 2023”, Randolf Kerschbaumer, CEO OncoOne.